Collaboration with a Major Company and Commercialisation of a Cauliflower Mushroom Product for Menopausal Women
First written in FY2021-Q1. 7 of 18 entries say "Softened", first in FY2023-Q3. Latest entry: 2026-11-12.
Intertrade moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Softened".
- FY2026-H1SoftenedAnnual report
「Because sales of IT Hanabiratake products were delayed from the plan, sales were essentially flat at ¥55 million, or 100.8% of the same period of the previous year. The company will seek to expand the business by developing EstroRich Pure, a new product that states the functionality of IT Hanabiratake.」
Although the policy of launching new products related to Foods with Function Claims remains unchanged, sales of IT Hanabiratake products were delayed from plan, and healthcare segment sales were essentially flat. - FY2025AdvancedAnnual report
「As announced in March 2025, we obtained a filing number from the Consumer Affairs Agency for the Foods with Function Claims designation for the “IT Hanabiratake” (cauliflower mushroom) product. The function of “reducing temporary feelings of fatigue, or susceptibility to fatigue, in the daily lives of healthy middle-aged and older women” is the first functionality accepted for a final product based on our own research and papers. Now that the efficacy of “IT Hanabiratake” for menopausal women has been demonstrated, we will target women experiencing menopausal symptoms and develop products with a greater emphasis on functionality.」
The company obtained the filing number for the Foods with Function Claims designation, which was accepted for the first time as a final product based on its own research and papers. It has moved toward developing products with an emphasis on functionality and targeting menopausal women. - FY2025-H1AdvancedAnnual report
「As announced on 28 March 2025, after obtaining a Foods with Function Claims notification number from the Consumer Affairs Agency, the company will launch “EstroRich Pure,” a new product that clearly states the functionality of “IT Hanabiratake,” from the third quarter of fiscal 2025 onward, with the aim of expanding the business.」
The company obtained the previously deferred filing number for the Foods with Function Claims designation and indicated the specific next step of launching new products from the accounting period for the third quarter of 2025 onward. - FY2024SoftenedAnnual report
「The company aimed to obtain the notification number for the Foods with Function Claims designation during the fiscal year ending September 2024, but was unable to do so during that period. As a result, it was also unable to launch the new product, causing a substantial delay in the sales plan. The company is currently making intensive preparations to launch the new product at an early stage of the fiscal year ending September 2025.」
The target of obtaining the Foods with Function Claims designation during the fiscal year ending September 2024 was not achieved, and the new product was not launched. The target for introducing the new product has been deferred to the early part of the fiscal year ending September 2025. - FY2024-Q2SoftenedAnnual report
「Although we are concerned about a deterioration in market conditions stemming from cases of harm to consumers who consumed health foods containing certain ingredients, our policy remains unchanged that obtaining a Foods with Function Claims filing number and stating scientifically supported functionality on product packaging will help provide products with greater appeal to consumers, raise product awareness and expand sales. Accordingly, although the schedule will be delayed, we will continue working to obtain the designation.」
The company is maintaining its policy of obtaining a Foods with Function Claims designation, but expressed concern about deteriorating market conditions following health problems caused by health foods and explicitly acknowledged a delay in the acquisition schedule. - FY2024-Q1RestatedAnnual report
「We continue to work toward obtaining a Foods with Function Claims designation and are preparing to sell a new “IT Hanabiratake” (cauliflower mushroom) product displaying its effects and efficacy during the current consolidated fiscal year. We are also working to expand the scale of the business and achieve profitability.」
The company continues to work toward obtaining the Foods with Function Claims designation and preparing to sell a new product displaying its effects and efficacy during the current consolidated fiscal year. Neither the designation nor the launch has been completed, and the company has reiterated its policy of expanding the business and achieving profitability. - FY2023SoftenedAnnual report
「We continue to take steps toward obtaining the Foods with Function Claims designation, with the aim of obtaining it during the fiscal year ending September 2024. By stating the functionality of IT Hanabiratake, we will develop products with greater appeal to consumers.」
The previous target of obtaining the designation during the fiscal year ending September 2023 was not achieved, and the target was deferred to the fiscal year ending September 2024. - FY2023-Q3SoftenedAnnual report
「Although obtaining the Foods with Function Claims designation for “IT Hanabiratake” (a cauliflower mushroom product) has been delayed from the initial plan, we are entering the final stage with the aim of obtaining it during the current fiscal year.」
The company explicitly stated that, although it is maintaining its target of obtaining the Foods with Function Claims designation during the current fiscal year, the process has been delayed from the initial plan. - FY2023-Q2RaisedAnnual report
「We are continuing preparations to obtain a Foods with Function Claims designation and aim to obtain it and launch a new product during the current consolidated fiscal year. By using the designation to state the functionality of “IT Hanabiratake” (a cauliflower mushroom product) for menopausal women, we will develop products with greater appeal to consumers.」
In addition to the previous target of obtaining the Foods with Function Claims designation, the company stated that it also aims to launch a new product during the current consolidated fiscal year, broadening the scope of its targets. - FY2022AdvancedAnnual report
「We are preparing to obtain a Foods with Function Claims designation and aim to obtain it during the fiscal year ending September 2023. By displaying the functionality of “IT Hanabiratake” (a cauliflower mushroom product) through this designation, we will develop products with greater appeal to consumers.」
As the next step following publication of the paper, the company set a time-bound target of obtaining the Foods with Function Claims designation during the fiscal year ending September 2023. - FY2022-Q3AdvancedAnnual report
「The publication in the academic journal Applied Pharmacology of a paper titled “Evaluation of the Efficacy and Safety of Hanabiratake in Relieving Unpleasant Symptoms of Menopause in Women” also increased inquiries about “IT Hanabiratake” from major health-food manufacturers, and the company is preparing for further sales growth.」
Inquiries from major health-food manufacturers increased following publication of the paper on human trials, and preparations are under way to expand sales of cauliflower mushroom products for menopausal women. - FY2022-Q2AdvancedAnnual report
「We plan to proceed with the filing for a Foods with Function Claims designation based on this academic paper. Now that the efficacy of “IT Hanabiratake” (a cauliflower mushroom product) for menopausal women has also been demonstrated academically, we will target women experiencing menopausal symptoms and develop products with a greater emphasis on functionality.」
Following the concrete progress of publication of a paper on human trials of cauliflower mushroom for menopausal women, the company plans to file for a Foods with Function Claims designation and develop products with an emphasis on functionality. - FY2022-Q1AdvancedAnnual report
「The supplements market addressing women’s health issues, known as the femcare market, is expanding. By promoting the benefits and efficacy of “IT Hanabiratake” to menopausal women, and with an increase in OEM transactions year on year, net sales increased to ¥36 million, or 106.6% of the year-earlier period.」
The company explained that claims regarding the effects and efficacy of cauliflower mushroom products for menopausal women, together with increased OEM transactions, led to higher sales of ¥36 million, up 106.6% year on year. - FY2021RestatedAnnual report
「We are continuing our research, using a new approach to obtain evidence on the effects and efficacy of “IT Hanabiratake” (a cauliflower mushroom product).」
The company continues its research into the effects and efficacy of IT Hanabiratake (a cauliflower mushroom product) and the acquisition of supporting evidence. - FY2021-Q3RestatedAnnual report
「We believe scientific evidence is necessary to further raise awareness of Hanabiratake, and are focusing on elucidating the mechanism of action and identifying the constituents responsible for the silent estrogenic activity contained in Hanabiratake.」
The company continues to focus on elucidating the mechanism of action and identifying the active compounds that will provide a scientific basis for collaborating on and commercialising cauliflower mushroom products for menopausal women. - FY2021-Q1First statedAnnual report
「The market for supplements addressing women-specific health concerns is expanding. As a result of our active sales efforts to date, major companies have shown strong interest in Hanabiratake targeting menopausal women. By identifying the constituents of Hanabiratake, elucidating its mechanisms of action and promoting its efficacy, we aim to develop products in collaboration with major companies.」
The company has for the first time set out a specific policy of identifying the active compounds in cauliflower mushroom for menopausal women and elucidating its mechanism of action, targeting the supplement market addressing health concerns specific to women, with the aim of commercialising products through collaboration with a major company.